CoChat
Sign Up
Cited by 124Proteoglycans and glycosaminoglycans researchOsteoarthritis Treatment and MechanismsLysosomal Storage Disorders Research

The DOI matches its Crossref record.

Chondroitin Sulfate and Chondroitin/Keratan Sulfate Proteoglycans of Nervous Tissue: Developmental Changes of Neurocan and Phosphacan

Meyer‐Puttlitz, Birgit, Milev, Peter, Junker, Ernst, Zimmer, Irene, Margolis, Richard U., Margolis, Renée K.·1995·Journal of Neurochemistry
DOI 10.1046/j.1471-4159.1995.65052327.x
Open this paper in CoChat — free account

Abstract

Abstract: We have studied developmental changes in the structure and concentration of the hyaluronic acid‐binding proteoglycan, neurocan, and of phosphacan, another major chondroitin sulfate proteoglycan of nervous tissue that represents the extracellular domain of a receptor‐type protein tyrosine phosphatase. A new monoclonal antibody (designated 1F6), which recognizes an epitope in the N‐terminal portion of neurocan, has been used for the isolation of proteolytic processing fragments that occur together with link protein in a complex with hyaluronic acid. Both link protein and two of the neurocan fragments were identified by amino acid sequencing. The N‐terminal fragments of neurocan are also recognized by monoclonal antibodies (5C4, 8A4, and 3B1) to epitopes in the G1 and G2 domains of aggrecan and/or in the hyaluronic acid‐binding domain of link protein. The presence in brain of these N‐terminal fragments is consistent with the developmentally regulated appearance of the C‐terminal half of neurocan, which we described previously. We have also used a slot‐blot radioimmunoassay to determine the concentrations of neurocan and phosphacan in developing brain. The levels of both proteoglycans increased rapidly during early brain development, but whereas neurocan reached a peak at approximately postnatal day 4 and then declined to below embryonic levels in adult brain, the concentration of phosphacan remained essentially unchanged after postnatal day 12. Keratan sulfate on phosphacan‐KS (a glycoform that contains both chondroitin sulfate and keratan sulfate chains) was not detectable until just before birth, and its peak concentration (at 3 weeks postnatal) was reached ∼1 week later than that of the phosphacan core protein. Immunocytochemical studies using monoclonal antibodies to keratan sulfate (3H1 and 5D4) together with specific glycosidases (endo‐β‐galactosidase, keratanase, and keratanase II) also showed that with the exception of some very localized areas, keratan sulfate is generally not present in the embryonic rat CNS.

Overview

Integrity signals

Registry

Crossref · 10.1046/j.1471-4159.1995.65052327.x

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Meyer‐Puttlitz, B., Milev, P., Junker, E., Zimmer, I., Margolis, R. U., & Margolis, R. K.
Affiliations
  • State University of New York (US)
  • NYU Langone Health (US)
Corresponding author
Margolis, Renée K.
Venue
Journal of Neurochemistry
Publisher
Wiley
Published
1995-11
Volume
65
Issue
5
Pages
2327-2337
ISSN
  • 0022-3042 (ISSN-L)
  • 1471-4159
DOI
10.1046/j.1471-4159.1995.65052327.x
OpenAlex
W2066045232
Cited by
124
References
0
Citations by year
2025: 2 · 2021: 3 · 2020: 2 · 2019: 1 · 2018: 2 · 2017: 2 · 2016: 1 · 2015: 7 · 2014: 5 · 2013: 3 · 2012: 1
FWCI
3.92
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor, 2579 d)
Locations
  • Journal of Neurochemistry (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (2k05mh000129-16)
  • National Institute of Mental Health (MH-00129)
  • National Institute of Neurological Disorders and Stroke (R01NS009348, NS-09348, R01NS013876, NS 13876)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Proteoglycans and glycosaminoglycans research
  • Health Sciences › Medicine › Rheumatology › Osteoarthritis Treatment and Mechanisms
  • Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
Keywords
neurocan, phosphacan, chondroitin sulfate proteoglycans, keratan sulfate, brain development, link protein, monoclonal antibodies, receptor-type protein tyrosine phosphatase, glycoforms, postnatal development
MeSH terms
Aging, Animals, Animals, Newborn, Chondroitin, Chondroitin Sulfates, Immunohistochemistry, Keratan Sulfate, Mice, Inbred BALB C, Nerve Tissue, Nerve Tissue Proteins, Chondroitin Sulfate Proteoglycans, Proteoglycans, Radioimmunoassay, Lectins, C-Type, Mice, Rats, Receptor-Like Protein Tyrosine Phosphatases, Class 5, Neurocan

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review